Michael Trocchia

Supply Chain Global Lead for Cell Therapy Products
Novartis

Mike started his career with Novartis in 1984 as a process engineer at the then Ciba-Geigy facility in Summit NJ. Mike steadily progressed to senior Process engineer in the Chemical Development group, overseeing the manufacture of Drug Substance used in clinical testing.

Mike then went on to manage the Commercial Drug Substance operations at the Summit site. His next assignment was to direct all Commercial Manufacturing operations at the Summit site before the site was closed and operations moved to alternate Novartis facilities.

Mike then moved to the Suffern, NY site as head of Quality Management and Training where he laid the groundwork for the very successful LEAN manufacturing implementation at the plant. In 2001, Mike moved to the Supply Chain Management organization at the East Hanover, NJ site.

Mike managed the Project management group in Supply Chain for all new Product launches, Production transfers, and Life cycle management changes for the Novartis US pharmaceutical business.

Mike’s latest role is Global Pharma Supply Chain lead for Cell Therapies. Mike has a BE degree in Chemical Engineering from Stevens Institute of Technology, a Master’s certificate in Project Management from The George Washington University, holds the APIC’s CPIM certification and is a licensed professional engineer in the state of NJ.

Check out the incredible speaker line-up to see who will be joining Michael.

Download The Latest Agenda

Supply Chain Effeciency Across the Global Network

Tuesday, May 9th, 2017

13:50 CASE STUDY: Managing Cold Chain Logistics for Cell Therapies – The Epitome of Personalized Medicine

Cell therapies are one of the most promising new classes of biopharmaceutical treatments available today but require a very specific set of conditions for transportation and distribution. In this session, Michael Trocchia, Supply Chain Lead for Cell & Gene Therapy Unit, will discuss the differences in cold chain logistics, including Small Molecule (Ambient transport), Biologics Large Molecule (Cold Chain 2-8C) and his area of focus, Cell and Gene Therapy very cold chains LN2(-190C). Specific to Cell Therapy Logistics, the talk will cover the factors related to the transportation of Cell and Gene Therapies:

Temperature Ambient/Dry Ice/LN2
Transport White Glove/Overnight Carriers
Tracking Active vs passive
Cost

14:10 Panel Discussion: The Spectrum Of Traditional Large Batch Molecules To Personalized Therapies And The Impact On The Supply Chain

Traditionally, the pharmaceutical supply chain has delivered scalable and conventional biopharmaceuticals. However, as more and more personalized products enter the market and immunology continues to deliver promising clinical therapies, smaller scale, alternative manufacturing and distribution approaches, methods of preservation, and fit with the endto- end supply chain will become the norm. With this continuum spanning from traditional large batch manufacturing of small molecule products to specialty treatments, there is significant differences in how supply chains should be managed and segmented. This panel will discuss:

Approaches needed to manage the variance of supply chains
What to expect from the integration of specialty pharmaceuticals, temperature controlled logistics, smaller volume production and more flexible manufacturing
Lessons learned and examples of how customized supply chains were managed